Najwa D. Aljehani

Jeddah, Saudi Arabia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Broadly Protective Antibody-Like Vaccines Against Highly Pathogenic Coronaviruses.

Broadly Protective Antibody-Like Vaccines Against Highly Pathogenic Coronaviruses.

Journal: Journal of medical virology

Published: October 06, 2025

Intranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice.

Intranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice.

Journal: Vaccine

Published: July 14, 2025

Correction: Full-length genome reveals genetic diversity and extensive recombination patterns of Saudi GI-1 and GI-23 genotypes of infectious bronchitis virus.

Correction: Full-length genome reveals genetic diversity and extensive recombination patterns of Saudi GI-1 and GI-23 genotypes of infectious bronchitis virus.

Journal: Virology journal

Published: March 25, 2025

Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals.

Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals.

Journal: mBio

Published: December 04, 2024

Full-length genome reveals genetic diversity and extensive recombination patterns of Saudi GI-1 and GI-23 genotypes of infectious bronchitis virus.

Full-length genome reveals genetic diversity and extensive recombination patterns of Saudi GI-1 and GI-23 genotypes of infectious bronchitis virus.

Journal: Virology journal

Published: September 26, 2024

ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks.

ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks.

Journal: Antibody therapeutics

Published: October 12, 2023

A Modified Recombinant DNA-Based SARS-CoV-2 Vaccine Expressing Stabilized Uncleavable Spike Protein Elicits Humoral and Cellular Immunity against Various SARS-CoV-2 Variants of Concern.

A Modified Recombinant DNA-Based SARS-CoV-2 Vaccine Expressing Stabilized Uncleavable Spike Protein Elicits Humoral and Cellular Immunity against Various SARS-CoV-2 Variants of Concern.

Journal: Transboundary and emerging diseases

Published: April 13, 2023

Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1.

Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1.

Journal: Vaccines

Published: June 26, 2021

Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia.

Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia.

Journal: Viruses

Published: June 07, 2021

Showing 1-9 of 9

Last Updated: 09/26/2026